Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

8:30 AM ET 8-K
Partnership Evolution Metals & Technologies Corp. EMAT

Evolution Metals & Technologies Partnership with VIVIFY Technology Corporation

Evolution Metals & Technologies (EMAT) signed a non-binding letter of intent with VIVIFY Technology to form a strategic energy collaboration. VIVIFY will serve as the primary hydrogen energy technology partner and infrastructure provider for EMAT's planned U.S. rare earth magnet campus. The partnership aims to provide behind-the-meter, near-zero-emission power to support power-intensive critical materials processing.

Counterparty
VIVIFY Technology Corporation
8:30 AM ET 8-K
Leadership Change Lifeward Ltd. LFWD

Lifeward Leadership Change

Lifeward Ltd. announced that Almog Adar's departure as CFO became effective on September 30, 2026. Interim CEO Josh Hexter has been designated to serve as the interim principal financial and accounting officer until Rami Aviram assumes the CFO role on November 1, 2026.

8:30 AM ET 8-K
Loan & Debt Americas Carmart Inc CRMT

Americas Carmart Debt Financing Update with Silver Point Finance, LLC

America's Car-Mart, Inc. entered into a further extension of its existing limited waiver and credit agreement amendment with Silver Point Finance, LLC, extending the termination date to October 8, 2026. The extension provides temporary relief regarding minimum liquidity and collateral coverage ratios while the company continues to evaluate strategic alternatives including potential financing or restructuring. The company is currently facing anticipated or existing events of default due to failures to comply with certain financial covenants.

Counterparty
Silver Point Finance, LLC
Term
through October 8, 2026
8:30 AM ET 8-K
M&A Deal Nsts Bancorp, Inc. NSTS

Nsts Bancorp Signs $73.7M M&A Deal with Brookfield Bancshares, Inc.

NSTS Bancorp, Inc. completed its merger with Brookfield Bancshares, Inc., with NSTS merging into Brookfield and its subsidiary bank becoming a wholly-owned subsidiary of Brookfield. Shareholders of NSTS received $14.31 per share in cash, representing an aggregate merger consideration of approximately $73.7 million. As a result of the transaction, NSTS common stock has been delisted from the Nasdaq Capital Market.

Value
$73.7M
Counterparty
Brookfield Bancshares, Inc.
8:23 AM ET 8-K
Loan & Debt Minerals Technologies Inc MTX

Minerals Technologies $400M Debt Financing

Minerals Technologies Inc. announced a private offering of $400 million in senior notes due 2034. The company intends to use the proceeds, along with cash on hand, to redeem its outstanding 5.000% senior notes due 2028 and to pay fees related to the offering and an amendment of its revolving credit facility.

Value
$400M
Term
10 years
8:22 AM ET 8-K
Business Update Casella Waste Systems Inc CWST

Casella Waste Systems Business Update

Casella Waste Systems announced that its NCES Landfill in Bethlehem, New Hampshire, will stop accepting municipal solid waste on December 31, 2026. This closure date is earlier than the previously expected end-of-2027 timeline due to updated evaluations of permitted airspace and fill rates. The company expects a higher level of landfill amortization expense in Q4 2026 as a result, though it does not anticipate a material impact on full-year financial results.

Counterparty
North Country Environmental Services landfill
8:21 AM ET 8-K
Capital Raise Banzai International, Inc. PARA

Banzai International Capital Raise

Banzai International entered into a subscription agreement with its CEO and Chairman, Joseph Davy, for the private placement of 115,965 shares of Class B Common Stock. The shares were sold at $0.70 per share for an aggregate cash purchase price of approximately $81,176. Following the transaction, Mr. Davy maintains a 25.6% voting interest in the company.

Counterparty
Joseph Davy
8:20 AM ET 8-K
Leadership Change Omega Healthcare Investors Inc OHI

Omega Healthcare Investors Leadership Change

Matthew P. Gourmand has been appointed as President and Chief Executive Officer of Omega Healthcare Investors, succeeding C. Taylor Pickett upon his retirement. Mr. Gourmand was also appointed to the Board of Directors to fill the vacancy created by Mr. Pickett's departure, effective October 1, 2026.

8:20 AM ET 8-K
M&A Deal Bnb Plus Corp. BNBX

Bnb Plus M&A Deal with Comstock Multichain Fund and KGPLA Holdings LLC

BNB Plus Corp. entered into a second amendment to its Registration Rights Agreement with holders of its registrable securities, including Comstock Multichain Fund and KGPLA Holdings LLC. The amendment removes the mandatory filing deadline for a resale registration statement and replaces it with a demand-based obligation, while also waiving any prior failures by the company to meet its registration obligations.

Counterparty
Comstock Multichain Fund and KGPLA Holdings LLC
8:17 AM ET 8-K
Other 8-K Filing Vylor Inc. VYLR

Vylor Other 8-K Filing

Vylor Inc. has completed its separation from Corteva, Inc. and is now an independent, publicly traded company. The separation was achieved through a pro rata distribution of Vylor common stock to Corteva shareholders of record as of September 24, 2026. Vylor common stock is expected to begin regular-way trading on the NYSE under the ticker symbol 'VYLR' on October 1, 2026.

Counterparty
Corteva, Inc.
8:17 AM ET 8-K
Court & Legal Update Parkervision Inc PRKR

Parkervision Court & Legal Update

The Court of Appeals for the Federal Circuit dismissed ParkerVision's appeal against Qualcomm for lack of jurisdiction and remanded the patent infringement case back to the District Court. ParkerVision intends to pursue a jury trial for its transmitter patent claims, where it is seeking approximately $440 million in damages, while preserving the right to appeal receiver patent claim constructions later.

Counterparty
Qualcomm
8:16 AM ET 8-K
M&A Deal SpyGlass Pharma, Inc. SGP

SpyGlass Pharma Signs $13M M&A Deal with Advanced Vision Science, Inc.

SpyGlass Pharma acquired 100% of the equity of Advanced Vision Science, Inc. (AVS) from Santen Holdings US for approximately $13 million in cash. The deal secures internal manufacturing capacity for the intraocular lenses (IOL) used in SpyGlass's Phase 3 drug delivery system and includes a supply agreement to continue providing products to Santen in Japan.

Value
$13M
Counterparty
Advanced Vision Science, Inc.
8:15 AM ET 8-K
Business Update Orchestra BioMed Holdings, Inc. OBIO

Orchestra BioMed Holdings Business Update

Orchestra BioMed exceeded its enrollment target for the BACKBEAT Global Pivotal Trial, randomizing 330 patients across 81 sites globally. The trial is evaluating AVIM Therapy for uncontrolled hypertension in pacemaker patients in collaboration with Medtronic. The company expects to submit primary endpoint data for presentation at a major cardiovascular conference in Q2 2027.

Counterparty
Medtronic plc
8:14 AM ET 8-K
Other 8-K Filing Corteva, Inc. CTVA

Corteva Other 8-K Filing

Corteva, Inc. completed the separation of its seed operating segment into an independent, publicly traded company named Vylor Inc. The spin-off was executed via a pro rata distribution of Vylor common stock to Corteva shareholders of record as of September 24, 2026. Vylor is expected to begin regular-way trading on the NYSE under the symbol 'VYLR' on October 1, 2026.

Counterparty
Vylor Inc.
8:13 AM ET 8-K
Leadership Change First Merchants Corp FRME

First Merchants Leadership Change

First Merchants Corporation announced that CEO Mark K. Hardwick will retire effective January 1, 2027, after 29 years with the company. Michael J. Stewart, the current President of First Merchants Bank, has been appointed to succeed him as President and Chief Executive Officer as part of a planned executive succession plan. Stewart has been with the bank for over 18 years and will assume the principal executive officer role upon Hardwick's retirement.

8:11 AM ET 8-K
Clinical Trial Data Azitra, Inc. AZTR

Azitra Clinical Trial Data

Azitra, Inc. has completed Cohort 1 of its Phase 1/2 clinical trial for ATR-04, a live biotherapeutic candidate for treating skin rash associated with EGFR inhibitors. Following a safety review committee clearance, the company is proceeding to enroll approximately 24 patients in Cohort 2 to further evaluate safety, tolerability, and preliminary efficacy.

8:06 AM ET 8-K
Business Update Aptera Motors Corp SEV

Aptera Motors Business Update

Aptera Motors announced a significant reduction in its estimated capital requirements to reach production, lowering the target to $25 million from a previous estimate of $40-$45 million. The company attributes these savings to its strategic partnership with Launch Design, which improved manufacturability and supplier access, and now expects to begin building its first 40 production vehicles by the end of 2026.

Counterparty
Shanghai Launch Automotive Technology Co., Ltd.

“This is a fundamentally leaner path to getting Aptera into customers’ hands. We’ve reduced our estimated capital requirements to reach production and brought what we believe could be a self-sustaining business within much closer reach.”

Chris Anthony, Co-CEO of Aptera

“By redesigning the Aptera for manufacturability and tapping Launch Design’s international supplier network, we believe we are pursuing one of the more capital-efficient paths to production in the EV industry.”

Chris Anthony, Co-CEO of Aptera
8:03 AM ET 8-K
Leadership Change Airgain Inc AIRG

Airgain Leadership Change

Airgain, Inc. appointed Stephan D. Memmen to its Board of Directors as a Class II director, effective October 1, 2026, increasing the board size from seven to eight members. In connection with his appointment, Mr. Memmen received $50,000 in restricted stock units and $50,000 in stock options, both vesting over three years, along with standard cash compensation for non-employee directors. Mr. Memmen brings extensive industry experience from prior leadership roles at Amphenol Corporation and Pulse Electronics.

Counterparty
Stephan D. Memmen
8:02 AM ET 8-K
Clinical Trial Data Evommune, Inc. EVMN

Evommune Clinical Trial Data

Evommune presented Phase 2a proof-of-concept data for EVO301 in patients with moderate-to-severe atopic dermatitis, showing a 55% mean reduction in EASI scores at Week 12 compared to 22% for placebo. The trial validated IL-18 inhibition as a novel therapeutic approach with a favorable safety profile, and the company plans to initiate a Phase 2b dose-ranging trial in mid-2027.

Counterparty
European Academy of Dermatology and Venereology (EADV)
8:01 AM ET 8-K
Dividend Strategy Inc MSTR

Strategy Dividend

Strategy Inc's board of directors declared semi-monthly cash dividends of $0.50 per share on its Variable Rate Series A Perpetual Stretch Preferred Stock (STRC), representing a 12.00% annual rate. The dividends are payable on October 31 and November 15, 2026, though the November payment is contingent on the outcome of a stockholder vote regarding Daily Dividend Amendments. The company intends to maintain the 12.00% rate until the preferred stock demonstrates sustained trading near $100 per share.

Term
Semi-monthly
8:01 AM ET 8-K
Divestiture Radnostix Inc INIS

Radnostix Divestiture to Nano Nuclear Energy Inc. for $13.5M

Radnostix Inc. entered into a definitive agreement to sell its depleted uranium deconversion and fluorine extraction assets, including an NRC license and related patents, to Nano Nuclear Energy Inc. for $13.5 million. The consideration consists of $9.5 million in cash and $4 million in Nano Nuclear restricted common stock, allowing Radnostix to focus on its core radioisotope technology segments.

Value
$13.5M
Counterparty
Nano Nuclear Energy Inc.
8:00 AM ET 8-K
Business Update Allarity Therapeutics, Inc. ALLR

Allarity Therapeutics Business Update

Allarity Therapeutics provided an operational update regarding its proprietary Drug Response Predictor (DRP) technology, patent portfolio, and in-house laboratory capabilities. The company highlighted that higher DRP scores were associated with longer overall survival in ovarian cancer patients treated with stenoparib, supporting its strategy to use the technology for patient selection in upcoming pivotal trials.

7:59 AM ET 8-K
Clinical Trial Data Nektar Therapeutics NKTR

Nektar Therapeutics Clinical Trial Data

Nektar Therapeutics announced long-term Phase 2b data for rezpegaldesleukin in patients with alopecia areata (REZOLVE-AA) and atopic dermatitis (REZOLVE-AD) at the EADV Congress 2026. The data demonstrated sustained hair regrowth and deepening of response even six months after treatment cessation, suggesting a differentiated regulatory T cell (Treg) mechanism compared to existing systemic therapies.

Earnings call
Oct 1, 2026, 3:00 PM ET
7:58 AM ET 8-K
Leadership Change USA Rare Earth, Inc. USAR

USA Rare Earth Leadership Change

USA Rare Earth, Inc. has completed its CEO succession plan, with Thras Moraitis officially assuming the role of Chief Executive Officer. Moraitis, who previously served as the company's President, succeeds Barbara Humpton and will focus on integrating the company's global rare-earth business units following the combination with Serra Verde.

7:57 AM ET Form 4
Insider Buying Filana Therapeutics, Inc. FLNA

Filana Therapeutics President & CEO Richard Barry Buys $278K of Stock

Richard Barry, President & CEO, bought 306,813 shares of Filana Therapeutics, Inc. at $0.9 to $0.92 a share (average $0.9065) in 2 transactions, worth $278K in total between Sep 29, 2026 and Sep 30, 2026. Shares held after the trade: 1,337,964 (+8.1%).

Value
$278K
Shares
306,813
Average price
$0.9065
Role
President & CEO
Holding change
+8.1%
Trade date
Sep 29, 2026 to Sep 30, 2026
7:55 AM ET 8-K
M&A Deal Armada Acquisition Corp. II XRPNU

Armada Acquisition Corp. II M&A Deal with Ripple Labs Inc.

Armada Acquisition Corp. II shareholders approved the business combination with Ripple Labs Inc. and Pathfinder Digital Assets LLC at an extraordinary general meeting. The transaction involves a merger and domestication of the company from the Cayman Islands to Delaware, where it will be renamed Arrington Capital SPAC I Inc. Approximately 69% of the shares entitled to vote were represented at the meeting to approve the deal.

Counterparty
Ripple Labs Inc.
7:51 AM ET 8-K
Capital Raise Veritone, Inc. VERI

Veritone Capital Raise of $15M

Veritone, Inc. entered into a securities purchase agreement for a registered direct offering of 20,000,000 shares of common stock at an implied price of $0.75 per share. The company expects to raise $15.0 million in gross proceeds to repay or restructure convertible debt and for general corporate purposes. The offering is expected to close on or about October 2, 2026.

Value
$15M
7:48 AM ET 8-K
Leadership Change Toast, Inc. TOST

Toast Leadership Change

Jonathan Vassil has notified Toast, Inc. of his decision to step down as Chief Revenue Officer, effective December 31, 2026. The departure is described as a planned retirement and not the result of any disagreement with the company. Mr. Vassil will remain with the company in a non-executive capacity through April 2, 2027.

7:46 AM ET 8-K
Capital Raise Brightline Interactive, Inc. BTLN

Brightline Interactive Capital Raise of $1.25M

Brightline Interactive closed a private investment in public equity (PIPE) raising $1.25 million in gross proceeds through the issuance of units of common stock and warrants. The financing was led by drone industry executive Dr. Allan Evans in his personal capacity to support the development of the SpatialCore Physical AI platform.

Value
$1.25M
Counterparty
Dr. Allan Evans
7:46 AM ET 8-K
Business Update Valion Bio, Inc. VBIO

Valion Bio Business Update

Valion Bio announced the successful completion of formulation work for a novel oral mucosal version of its radiation protection biologic, Entolimod, using Shear Kershman Laboratories' BioViscid platform. This milestone creates a potential needle-free delivery pathway that could significantly expand the addressable market for radiological emergency deployment. The company plans to move into studies testing systemic delivery into the bloodstream next.

Counterparty
Shear Kershman Laboratories

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.